Literature DB >> 8077717

Degradation of C3 by Streptococcus pneumoniae.

C S Angel1, M Ruzek, M K Hostetter.   

Abstract

After growth to exponential phase in Todd-Hewitt broth, clinical and laboratory isolates of Streptococcus pneumoniae serotypes 3, 4, and 14 readily degraded first the beta and then the alpha chains of purified human C3 in the absence of serum or other complement proteins, as assessed by SDS-PAGE. With exponentially growing pneumococci, degradation of native C3 was detectable within 30 min; methylamine-treated C3 and preformed C3b were degraded with equal avidity. Pneumococcal C3-degrading activity was cell associated, abolished by heat killing, and independent of the presence of the polysaccharide capsule. After degradation, 44% of C3 molecules contained a disrupted thiolester bond. Pneumococci treated with 100 micrograms of mutanolysin released 94% of C3-degrading activity from the pneumococcal surface into the supernatant. These studies demonstrate that clinical and laboratory isolates of virulent pneumococci degrade and inactivate soluble C3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077717     DOI: 10.1093/infdis/170.3.600

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 2.  Common themes in microbial pathogenicity revisited.

Authors:  B B Finlay; S Falkow
Journal:  Microbiol Mol Biol Rev       Date:  1997-06       Impact factor: 11.056

3.  Recovery of Streptococcus iniae from diseased fish previously vaccinated with a streptococcus vaccine.

Authors:  G Bachrach; A Zlotkin; A Hurvitz; D L Evans; A Eldar
Journal:  Appl Environ Microbiol       Date:  2001-08       Impact factor: 4.792

4.  Pleiotropic effects of cell wall amidase LytA on Streptococcus pneumoniae sensitivity to the host immune response.

Authors:  Elisa Ramos-Sevillano; Ana Urzainqui; Susana Campuzano; Miriam Moscoso; Fernando González-Camacho; Mirian Domenech; Santiago Rodríguez de Córdoba; Francisco Sánchez-Madrid; Jeremy S Brown; Ernesto García; Jose Yuste
Journal:  Infect Immun       Date:  2014-11-17       Impact factor: 3.441

5.  Streptococcus iniae virulence is associated with a distinct genetic profile.

Authors:  J D Fuller; D J Bast; V Nizet; D E Low; J C de Azavedo
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Innate immune defense against pneumococcal pneumonia requires pulmonary complement component C3.

Authors:  Alison R Kerr; Gavin K Paterson; Alan Riboldi-Tunnicliffe; Tim J Mitchell
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  Interaction of pneumococcal histidine triad proteins with human complement.

Authors:  Merit Melin; Emmanuel Di Paolo; Leena Tikkanen; Hanna Jarva; Cecile Neyt; Helena Käyhty; Seppo Meri; Jan Poolman; Merja Väkeväinen
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

8.  Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Authors:  Bing Ren; Alexander J Szalai; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Role of complement in host defense against pneumococcal otitis media.

Authors:  Vishakha Sabharwal; Sanjay Ram; Marisol Figueira; In Ho Park; Stephen I Pelton
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

Review 10.  Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Authors:  E AlonsoDeVelasco; A F Verheul; J Verhoef; H Snippe
Journal:  Microbiol Rev       Date:  1995-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.